Lyphomed/B-ORG Inc./I-ORG ,/O Rosemont/B-GPE ,/O Ill./B-GPE ,/O and/O Medco/B-ORG Research/I-ORG Inc./I-ORG ,/O Los/B-GPE Angeles/I-GPE ,/O said/O the/B-ORG Food/I-ORG and/I-ORG Drug/I-ORG Administration/I-ORG granted/O full/O marketing/O approval/O for/O a/O new/O drug/O for/O the/O treatment/O of/O a/O condition/O in/O which/O the/O heart/O beats/O between/O 150/O and/O 200/O beats/O a/O minute/O ./O
The/O condition/O ,/O known/O as/O paroxysmal/O supraventricular/O tachycardia/O ,/O leads/O to/O dizziness/O and/O fainting/O ./O
The/O typical/O healthy/O heart/O beats/O 70/O times/O a/O minute/O ./O
The/O drug/O ,/O called/O adenocard/O ,/O returns/O the/O heart/O to/O a/O normal/O rhythm/O within/O seconds/O ,/O according/O to/O Lyphomed/B-ORG ./O
Medco/B-ORG Research/I-ORG developed/O the/O drug/O and/O licensed/O it/O to/O Lyphomed/B-ORG for/O sale/O in/O the/O U.S./B-GPE and/O Canada/B-GPE ./O
